Cymra receives its ODC permit
Cymra has been granted permits from the Office of Drug Control for cultivation and manufacture on its site in the Northern Rivers of NSW The permit allows Cymra to grow commercial crops for sale to licensed parties as well as extract cannabis to produce oils. This is a big milestone for the team based on […]
CYDEPS Dose Escalation Pain Study
CYDEPS – Dose escalation pain study The CYDEPS clinical trial is investigating the use of a medical cannabis product as a potential treatment for chronic back and/or neck pain. The study is a single arm, open label clinical study which means everyone who participates will receive the experimental medication (there is no placebo). The clinical […]
Cybis 10:25 Released
Cymra’s flagship clinical product Cybis is now released an on the market through our distributor. Its Australian grown cannabis under Good Agricultural Practice and Australian manufactured under Good Manufacturing Practice. Full spectrum profile with Linalool the dominant terpene, alongside bisabolol and betacaryophellene providing potential benefits of the entourage effects. Linalool has shown to reduce anxiety […]
John Montgomery joins the Cymra Life Sciences Board of Directors
Cymra Pharma is pleased to announce John Montgomery as an Executive Director to the Board. John comes with 40yrs of pharmaceutical experience in the US, Europe and Asia. John was CEO of Alphapharm and Regional Director, Asia Pacific for Merck Generics. Following the Mylan acquisition he was President, Mylan Asia Pacific for 11 years from […]